Pharmaceutical particles design by membrane emulsification: preparation methods and applications in drug delivery

This item was submitted to Loughborough University's Institutional Repository by the/an author.


Additional Information:


Metadata Record: https://dspace.lboro.ac.uk/2134/25455

Version: Accepted version

Publisher: © Bentham Science Publishers

Rights: This work is made available according to the conditions of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence. Full details of this licence are available at: https://creativecommons.org/licenses/by-nc-nd/4.0/

Please cite the published version.
Pharmaceutical Particles Design by Membrane Emulsification: preparation methods and applications in drug delivery

Emma Piacentini1*, Marijana Dragosavac2, Lidietta Giorno1

1Institute on Membrane Technology, National Research Council, ITM-CNR, Via P. Bucci 17/C at University of Calabria, 87036 Rende (CS), Italy

2Department of Chemical Engineering, Loughborough University, LE11 3TU, UK

*Correspondence: e-mail: e.piacentini@itm.cnr.it; Tel.: +39 0984 49 20 51
ABSTRACT
Nowadays, the rational design of particles is an important issue in the development of pharmaceutical medicaments. Advances in manufacturing methods are required to design new pharmaceutical particles with target properties in terms of particle size, particle size distribution, structure and functional activity. Membrane emulsification is emerging as a promising tool for the production of emulsions and solidified particles with tailored properties in many fields. In this review, the current use of membrane emulsification in the production of pharmaceutical particles is highlighted. Membrane emulsification devices designed for small-scale testing as well as membrane-based methods suitable for large-scale production are discussed. A special emphasis is put on the important factors that contribute to the encapsulation efficiency and drug loading. The most recent studies about the utilization of the membrane emulsification for preparing particles as drug delivery systems for anticancer, proteins/peptide, lipophilic and hydrophilic bioactive drugs are reviewed.

Keywords: Membrane emulsification, emulsions, particles, drug delivery, encapsulation efficiency, stimulus responsive, administration route, pharmaceutical field.
INTRODUCTION

During the last decade, membrane emulsification has emerged as one of the most interesting technologies in pharmaceutical particle design [1 E. Piacentini, 2014]. In the membrane emulsification process, monodisperse droplets are generated by dispersing one liquid (dispersed phase) into a second, immiscible liquid (continuous phase) through the pores of a membrane (Figure 1 A). The droplet size and droplet size distribution are mainly determined by the membrane properties (pore size, pore size distribution, membrane wettability). The optimization of the operating conditions (dispersed phase flux and shear stress) as well as of composition of the phases (density of phases and viscosity, emulsifier type and concentration) allows the production of uniform, reproducible and size-controlled droplets [2,3 Joscelyne, 2000; Charcosset, 2004].

In the physical sciences, a particle represents a small localized object to which can be ascribed several physical properties such as volume or mass. Particles may be solid, but they also may be liquid droplets dispersed in another immiscible liquid or air. There is a great demand from pharmaceutical industry to improve the production methods of both organic and inorganic uniform spherical particles. An emulsion is a dispersion of one liquid in another where the liquids are not miscible, or are slightly soluble, and they play a valuable role in the production of the particle. Emulsion droplets are already particles but, even more, the droplets after production may be converted into solid particles by applying an additional physical (fluidized bed coating, spray or freeze-drying, evaporation/solvent diffusion) or chemical (reacting, coacervation and interfacial polymerization) treatments [4 Dragosavac M.M 2011]. The fabrication of uniform size micro-/nano-particles with well-defined properties is an essential requirement for the application in pharmaceutical field. Particles with heterogeneous size distribution are difficult to reproduce and control accurately during manufacturing and may cause an unpredictable and unreproducible release profiles with poor therapeutic effects [5, 6Wu, J., 2015; Liu, W., 2010]. Particle size plays an important role in biodistribution, targeting, uptake mechanisms, degradation and clearance. The choice of the emulsification process is a key issue in the particle production as it influences directly the final size, and size distribution, of the solid particles. Furthermore, particles size and size distribution are also directly influencing the rate of drug release which usually is the most important parameter in pharmaceutical industry. Some important challenges are required for the advancement of technologies in engineering particles with improved functional and structured properties:

i) Maintaining the performance of a good emulsification step when the process is transferred from the laboratory scale to a larger throughput scale [7 Huang et al. 2008], and

ii) Achieving a precise control of particle size and size distribution in the emulsification step while maintaining the incorporation of biomolecules without affecting their activity; the distribution in the body; the interaction with living cells as well as the drug release kinetics of the solid particles are greatly influenced by their size and uniformity [8 Benita 2006].

There are many conventional ways for preparing emulsions. In such devices, a premix emulsion is necessary, which is produced by gentle mixing, followed by homogenization which will lead to further reduction of the droplet size. In general, homogenization is an intense process: it introduces a large amount of energy into the premix emulsion to break up the droplets into smaller ones. In high-pressure systems, premix is pushed through a small valve at high pressure. Due to the high shear and extension rates in the valve, large droplets break up into smaller. In stirring vessels the droplets break up is due to the paddle stirring. The average input per unit volume is quite low and they are suitable for production of coarse emulsions, and mainly used as batch systems. In Colloidal mills, premix is pushed through the gap between a cylindrical or conical stator and rotor. Due to the shear and extension exerted by the rotor, large droplets break up into smaller ones. A laboratory homogeniser uses a very similar principle to this. In Toothed disk dispersing machines, premix is pushed through the gap between several pairs of concentrically arranged disks of various designs, one of which rotates.
due to shear and large droplets break up. In Ultrasound systems, premix is placed in a vessel with an ultrasound device. Due to the intense turbulence caused by the ultrasound waves, the droplets break up into smaller ones.

Conventional homogenizers, as mentioned above, are very convenient for production of small size droplets below 10 µm [9 Karbshtein and Shubert 1995]. For production of larger droplets low shear needs to be applied, but conventional homogenisation in that case produces droplets with a wide size distribution. Such a product is often unstable and has unsatisfactory properties [4 Dragosavac M.M. 2011].

Membrane emulsification demonstrated a remarkable capability in tuning droplet size and size distribution of particles. Process flexibility led to its application in a variety of solid and advanced particles formulations for drug protection or controlled release. In addition, high encapsulation and loading efficiencies of an active pharmaceutical ingredient as well as the maintenance of the bioactivity of protein/peptide drugs can be achieved due to mild fluid-dynamic conditions.

Another challenge facing particles as drug delivery systems is the large-scale production of micro-nanostructured materials in terms of scaling up laboratory or pilot technologies for consistent and reproducible production and commercialization. The membrane emulsification process is attractive for the production of particles with homogeneous size distribution at large scale by increasing membrane area. Principles, controlling parameters and applications of membrane emulsification are reviewed in previous works [1-3, 5, 10-22] [1–12; Wang, 2015, Wu, 2015, Ma, 214, Vladisavljević G. T., 2015, Piacentini 2014]. As demonstrated by a patent analysis, the major area of application of membrane emulsification is in the medical field [1 Piacentini 2014]. The use of particles prepared by membrane emulsification in the medical field has been recently reviewed [5, 6, 21, 22 Wang, 2015, Wu, 2015, Ma, 214, 9]. The recognized benefits of membrane emulsification in pharmaceutical particle production is demonstrated by the increasing number of paper published in this field in the recent years (Figure 2).

In this review, the power of membrane emulsification to assist the fabrication of pharmaceutical particles with tuned size, size distribution, structure, and surface properties is highlighted. In particular, this article focuses on the advances of pharmaceutical particles prepared by membrane emulsification, including devices for small and large scale application. Special emphasis has been put on the main factors to be considered for pharmaceutical particles design such as particle structure, administration route, targeting properties, drug loading and encapsulation efficiency. The most recent studies about the utilization of the membrane emulsification technique for preparing particles as drug delivery systems for anticancer, proteins/peptide, lipophilic and hydrophilic bioactive drugs are described.

**FABRICATION of PHARMACEUTICAL PARTICLES BY MEMBRANE EMULSIFICATION**

The formulation, development and manufacture of pharmaceutical products based on particles ranges from the start of formulation optimization to final drug marketing. The membrane emulsification process provides suitable solutions for pharmaceutical particles generation at different levels:

i) Bench and lab scale testing of formulation can be performed to produce particles and emulsions with tuned structure and functional properties.
ii) Large scale production of emulsions and particles can be carried out by transferring meaningful laboratory data for process scale-up.

iii) Continuous manufacturing process can be developed by connecting in series the membrane emulsification plant with a reactor to achieve simultaneous drop generation and chemical/physicochemical reaction in the produced emulsion.

Membrane emulsification devices designed for small-scale testing are commercially available to establish the effectiveness of the membrane-based method in association with the desired formulation (Figure 3).

**BENCH AND LAB-SCALE MEMBRANE EMULSIFICATION DEVICES**

![Membrane Emulsification Diagram]

Figure 3. Membrane emulsification for droplets production at bench/lab-scale

SPG Technology Co., Ltd (Japan) developed membrane emulsification microkits that require only 8–50 mL of the continuous phase per single batch, which is useful for expensive clinical preparations as well as for preliminary tests for formulation optimization. In the internal-pressure type system, the inside of tube-shaped membrane is filled with the dispersed phase liquid and, the outside, with the continuous phase liquid [23 J. Lee, 2010]. The pressure is given to the inside of the membrane by use of nitrogen gas and the continuous phase is stirred by using a rotator. In the external-pressure type system, the outside of a tube-shape is filled with the dispersed phase liquid, and the inside, with the continuous phase liquid [24 L. Chu, 2003]. The pressure is given from outside to inside of SPG membrane by using nitrogen gas and the continuous phase is stirred by using a rotator. A simplified experimental set-up, suitable for bench and lab scale tests, can be used in the case of static membrane emulsification. In this method, the formation of emulsion droplets occurs in the absence of surface shear [25 Kukizaki M (2009)]. Micropore Technologies (UK) developed the Dispersion Cell in which the dispersed phase is pumped through a circular disc membrane while a gentle shear is applied by using a paddle blade stirrer, positioned above the membrane [26 M.T. Stillwell, 2007].

Many strategies have been introduced in membrane-based emulsification to meet the demanding requirements for the production of emulsions and particles with high productivity without losing the good control on particle size and particle size distribution and operating at low shear and in gentle conditions (Figure 4). They differ on the way in which the surface shear (that results in droplet detachment from the pore openings) is generated: i) by moving the continuous phase in cross-flow or pulsed mode or ii) by moving the membranes by rotation, vibration or oscillation. The dispersed phase is injected through the membrane pores by using a pump or nitrogen gas. Membrane emulsification equipment suitable for large scale production and based on the use of moving and static membranes are commercialized by SPG Technology Co., Ltd (Japan) and Micropore Technologies (UK).

In cross-flow membrane emulsification, the shear stress is generated by the recirculation of the continuous phase tangentially to the membrane surface [27 Peng and Fellow, 1998]. The method is suitable for large-scale production and continuous or semi-continuous operation. However, droplet break-up can occur over time when concentrated emulsions are produced due to the high cross-flow velocities used to obtain narrow droplet size distribution at high dispersed phase flux, or over long time of operation.

In pulsed flow membrane emulsification, a periodic flow pulsation is generated in the continuous phase without recirculation. The pulsed flow in the continuous phase is generated by a frequency generator ([28 Holdich et al. 2013] or by inverting the flow direction back-and-forward within the membrane lumen [Piacentini et al. 2014][29]. The method is advantageous for the production of emulsions with a high dispersed to continuous phase ratio and it is suitable for large-scale production in continuous or semi-continuous mode.

In an alternative, the shear stress on the membrane surface can be generated by moving the membranes by rotation, vibration or oscillation. In rotating membrane emulsification, the dispersed phase is introduced into the center of a rotating
tubular porous membrane, and droplets are detached at the membrane wall in the radial direction into the stationary continuous phase [20] (Vladisavljević & Williams 2006). However, the use for large scale production is limited due to the complicated and more expensive design and higher power consumption compared to alternative designs. In vibrating membrane emulsification, the membrane oscillates perpendicularly with respect to the dispersed phase injection direction [30] (Holdich et al. 2010). The frequency and amplitude of the axial oscillation of the membrane is generated by an electrically driven vertical oscillator and can be controlled separately. The two methods are particularly advantageous for the production of relatively coarse emulsions and fragile structured products in which the droplets and/or particles are subject to breakage during the pump recirculation. In azimuthally oscillating membrane emulsification, a tubular membrane is periodically rotated back-and-forward in a slowly cross flowing continuous phase [31] (Silva et al. 2015). The method operates in a continuous mode and it is suitable for large-scale production providing high production rates, facilitating easy process automation and reduced operation time.

**LARGE SCALE MEMBRANE EMULSIFICATION PLANTS**

![Diagram of membrane emulsification for droplets production at large-scale](image)

Figure 4. Membrane emulsification for droplets production at large-scale
For preparing small droplets with high productivity, another membrane emulsification technique, premix membrane emulsification, has been developed [32 Suzuki 1996]. In premix membrane emulsification, a coarsely emulsified mixture of two immiscible liquids (pre-emulsion) is passed through a microporous membrane (Figure 1 B). The advantages of this method over direct membrane emulsification (Figure 1 A) are that smaller droplet sizes and higher productivity can be achieved for the given pore size but at the expense of lower degree of monodispersity. The method is suitable for large scale production in continuous or semi-continuous mode however the emulsion has repeatedly to be passed through the same membrane in order to achieve additional droplet size reduction and improve droplet size uniformity. Premix membrane emulsification equipment has been developed by SPG Technology Co., Ltd (Japan) and National Engineering Research Centre for Biotechnology (Beijing) and Zhongke Senhui Microsphere Technology (Suzhou, China) Co. Ltd. For pharmaceutical particles, scale-up without failure is a key issue. Automatic control can avoid failure of large-scale production, especially for the direct membrane emulsification process. An automatic SPG membrane emulsification equipment for large-scale production and suitable for both direct and premix process equipped with temperature and parameters of production process control systems is commercialized by Zhongke Senhui Company.

Pharmaceutical particles with target size, uniform size distribution and a reasonable productivity for specific industrial requests, can be obtained by tuning operational, formulation and membrane parameters. General rules governing particle production by membrane emulsification to achieve control over the particle size, uniform particle size distribution and high productivity are summarized in Table 1.

Table 1. General rules to tune particle size, particle size distribution and process productivity by membrane emulsification process.

<table>
<thead>
<tr>
<th>Tuned Particle size</th>
<th>Uniform Particle size distribution</th>
<th>High Productivity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Membranes with pore size lower than the target particle size (Dp = x Dd, 0.1&lt;x&lt;0.5 (Katoh et al. 1996)) [33]</td>
<td>Membranes with uniform pore size distribution</td>
<td>Membranes with larger pore size and higher porosity</td>
</tr>
<tr>
<td>Membranes un-wetted by the dispersed phase. Hydrophilic and hydrophobic membrane are used for production of O/W and W/O emulsion, respectively (Piacentini et al. 2014). [34]</td>
<td>Membranes with low porosity and controlled pore distance in order to avoid droplets coalesce at the pore level [Kobayashi et al. 2002] [37]</td>
<td>Asymmetrically wetted membranes (membranes pore wall with good wettability to the dispersed phase allows a quick permeation of the phase in the pores (Piacentini et al. 2014). [34]</td>
</tr>
<tr>
<td>High shear stress generated on the membrane surface by moving the membranes or the continuous phase (Katoh et al. 1996). [33]</td>
<td>High shear stress and low dispersed phase flux to obtain droplets detachment from the pore before that droplets coalescence occur [Piacentini, 2016] [35]</td>
<td></td>
</tr>
<tr>
<td>Low dispersed phase flux. Particle size proportionally increases as a function of the dispersed phase flux increase [Piacentini, 2016] [35]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreasing the interfacial tension between the dispersed and continuous phase. Emulsifiers that quickly adsorb to the newly formed interface allow the production of particles with smaller size (Schröder et al. 1998) [36]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

PHARMACEUTICAL PARTICLE DESIGN

Development of micro-/nano-carriers with different structures

Emulsion droplets produced by membrane emulsification are used for the production of different micro-/nano-carriers by integration with various secondary reactions [19 Vladisavljevic, 2015]. In the present review, pharmaceutical particle fabrication by integration of membrane emulsification and various secondary reactions is described (Table 2). O/W and W/O emulsions produced by membrane emulsification have been used to produce pharmaceutical micro-/nano particles with tuned structure such as gel microbeads, solid lipid particles, micro/nanospheres, liquid-core/polymer-shell particles, polymer core/polymer-shell, complex coacervates and colloidosomes (Figure 5 and 6, Table 2). Biodegradable materials such as Poly(lactic-co-glycolic acid) (PLGA), Polycaprolactone (PCL), Sodium Alginate, Chitosan, poly(L-lactide) (PLLA), Eudragit, etc are employed. The nature of the drug to encapsulate (hydrophilic or hydrophobic) and the
target application, including organ delivery, administration route, stimulus responsive properties, controlled release, determine the selection of the wall material.

Production of micro-/nano-carriers from o/w emulsions

Figure 5. Micro-/nano-carriers production starting from o/w emulsions by integrating membrane emulsification with various secondary reactions.

Production of micro-/nano-carriers from w/o emulsions

Figure 6. Micro-/nano-carriers production starting w/o emulsions by integrating membrane emulsification with various secondary reactions.

Gel microbeads are spherical hydrogel microparticles produced by injecting an aqueous solution containing the polymer through the membrane pores followed by cross-linking reaction. The cross-linking reaction can be carried out by:
Internal gelation. The polymer (i.e. Na-alginate) and the crosslinking agent in non-dissociated form (i.e. CaCO₃) are suspended in the dispersed phase [38, 39 Liu, 2003, Hanga, 2014]. After emulsion production, a species (i.e. H⁺) is added in the continuous phase in order to diffuse into the droplets and activate the crosslinking agent forming the solid beads.

External gelation. The polymer (i.e. Na-alginate, Chitosan) is dissolved in the dispersed phase and the crosslinking agent (Ca++, glutaraldehyde, tripolyphosphate) is added after emulsion production, forming the solid beads [40- 46 You, 2001; Wang, 2005; Akamatsu, 2010; Lv, 2009; Ma, 2010; Lai, 2015].

Gel formation by cooling. The emulsification is carried out at a temperature higher than the temperature to coil-to helix transition of the polymer (gelatine, agarose) [47-49 Zhou, 2007; 2008; 2009]. Gel beads are obtained by cooling the resultant W/O emulsion.

Gel formation by droplet merging. Two W/O emulsions are mixed: one containing droplets of the polymer solution (i.e. Na-alginate) and the other containing droplets of the cross-linking agent (CaCl₂) [42, 50 Akamatsu, 2010; Nan, 2014]. Gel beads are produced by droplets merging.

Gel formation by heating. A W/O emulsion containing the polymer (quaternized chitosan, proteins) is heated at the gelation temperature of the polymer promoting chain interaction otherwise not possible at room temperature [51, 52 Wu, 2008; Surh, 2005].

Solid lipid particles are particles formed from lipids that are solid at room temperature (i.e. saturated fatty acids, esters of glycerol and Polyethylene glycol (PEG)) [53, 54 Kukizaki, 2007; Laouini, 2014]. O/W, W/O/W and S/O/W emulsions are produced at the above the melting point followed by cooling the emulsion below the melting point.

Micro/nanospheres are matrix type particles (entire mass is solid) while micro/nanocapsules are vesicular system in which a liquid core is surrounded by a polymeric membrane. Micro/nanospheres and micro/nanocapsules are produced from O/W and W/O/W or S/O/W emulsions containing a hydrophobic polymer (i.e. PLA, PLGA, PELA, PCL) dissolved in the oil phase, respectively [55- 60 Imbrogno, 2014; Ito, 2011; Doan, 2011; Ito, 2004; Zhang, 2015]. Solvent removal from the oil phase allows obtaining the solidified particles.

Micro/nanocapsules are matrix type particles (entire mass is solid) while micro/nanocapsules are vesicular system in which a liquid core is surrounded by a polymeric membrane. Micro/nanospheres and micro/nanocapsules are produced from O/W and W/O/W or S/O/W emulsions containing a hydrophobic polymer (i.e. PLA, PLGA, PELA, PCL) dissolved in the oil phase, respectively [55- 60 Imbrogno, 2014; Ito, 2011; Doan, 2011; Ito, 2004; Zhang, 2015]. Solvent removal from the oil phase allows obtaining the solidified particles.

Liquid-core/polymer-shell particles are produced from O/W emulsions in which the oil phase contains a hydrophobic polymer, a volatile water-immiscible good solvent for the polymer and non-volatile water-immiscible non-solvent [61, 62 Sawalha, 2008; Wagdare, 2011]. Solvent removal causes the formation of the solid shell because of polymer precipitation.

Polymer core/polymer-shell capsules are produced combining solvent evaporation with interfacial polymerization starting from O/W emulsion. The dispersed phase contains polymer and a hydrophobic monomer, while the continuous phase contains a hydrophilic monomer [63 Chu, 2002]. After solvent evaporation, the new formed polymer formed a polymer shell around the other polymer. Alternatively, the dispersed phase contains the hydrophobic monomer while the hydrophilic monomer is added in the continuous phase and the polycondensation precedes at the surface of the organic droplets.

Complex coacervates can be formed by mixing a polyanionic polymer (i.e. polysaccaraide) with a polycationic polymer (i.e. protein from animal and vegetal source). Polymers with opposite charges stick together and form soluble and insoluble complexes, depending on solutions concentration and pH, which are deposited around oil droplets forming a shell [64 Piacentini, 2013].

Colloidosomes are microcapsules that consist of a hollow core coated by a shell composed of self assembled colloidal particles and they are produced from a Pickering emulsion (a particles stabilized emulsion) after polymer deposition [65 Nan, 2014].

Representative figures of particles produced by membrane emulsification process are reported in Figure 7.
Figure 7. Particles produced by membrane emulsification coupled with; A-B) complex coacervation (core-shell particles); C-D) solvent diffusion (biodegradable polymer particles) and D-E) drying (inorganic particles).
Table 2. Examples of structured particles for application in pharmaceutical field fabricated by integration of membrane emulsification and secondary reaction

<table>
<thead>
<tr>
<th>Particles</th>
<th>Secondary reaction</th>
<th>Wall Material</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gel microbeads</td>
<td>Internal gelation from W/O emulsion</td>
<td>Sodium Alginate</td>
<td>38, 39 Liu, 2003 Hanga, 2014</td>
</tr>
<tr>
<td></td>
<td>Gel formation by cooling from W/O emulsion</td>
<td>Agarose</td>
<td>47–49 Zhou, 2007; 2008; 2009</td>
</tr>
<tr>
<td></td>
<td>Gel formation by droplet merging from W/O emulsion</td>
<td>Chitosan Alginate</td>
<td>42, 50 Akamatsu, 2010 Nan, 2014</td>
</tr>
<tr>
<td></td>
<td>Gel formation by heating from W/O emulsion</td>
<td>Chitosan Whey protein isolate</td>
<td>51, 52 Wu, 2008 Surh, 2005</td>
</tr>
<tr>
<td>Polymer core/polymer-shell capsules</td>
<td>Interfacial polymerization/Solvent removal from O/W emulsion</td>
<td>poly(d, l-lactide-co-glycolide)/poly(ethyl 2-cyanoacrylate)</td>
<td>23 Lee, 2010</td>
</tr>
<tr>
<td>Porous particles</td>
<td>Interfacial polycondensation</td>
<td>poly(N-isopropylacrylamide) (PNIPAM)</td>
<td>63 Chu, 2002</td>
</tr>
<tr>
<td>Complex Coacervates</td>
<td>Complex coacervation</td>
<td>Gelatin-Gum Arabic</td>
<td>64 Piacentini, 2013</td>
</tr>
<tr>
<td>Colloidosomes</td>
<td>Interfacial particle self-assembly</td>
<td>Alginate-Chitosan</td>
<td>65 Nan, 2014</td>
</tr>
</tbody>
</table>

**Targeting of particles**

Recent years have witnessed increasing attention to stimulus responsive drug carrier polymers because their properties can be tailored to fit the requirements required for drug delivery. Triggering mechanisms for micro-nanoparticles release include biological, chemical, photo, thermal, electrical, and magnetic stimuli. The combination of stimuli-responsive materials and membrane emulsification method allows designing particles with tailored smart and responsive properties for pharmaceutical applications. In this paragraph, such examples the design of stimulus responsive carriers by membrane emulsification process will be highlighted.

Thermoresponsive microparticles have been obtained by coating the alginate beads produced by membrane emulsification with Poly-N-isopropylacrylamide (pNIPAM) [39 M. P. Hanga, 2014]. The amino groups from the amine terminated pNIPAM form polyelectrolyte complexes with carboxylic acid groups in the alginate network. Temperature induced
transition of the amine-terminated pNIPAM in aqueous solution has been demonstrated to be a function of the pH. The protonation of amino groups of the amine-terminated pNIPAM modified the intra-molecular electrostatic forces by modifying the temperature-induced collapse of the modified polymer chains. Thermoresponsive microcapsules suitable for drug delivery systems have been developed by using a porous membrane and a linear-grafted poly(N-isopropylacrylamide) (PNIAPAM) chains in the membrane pores acting as thermoresponsive gates [63 Chu, 2002]. The preparation was carried out by using membrane emulsification and interfacial polymerization to prepare the core-shell microcapsules. The “on/off” of vitamin B12 due to the closed/open state of the grafted “gates” was achieved.

pH responsiveness has been produced polysaccharide particles prepared by membrane emulsification method [70, 71 Zhang, 2011; Lv, 2011]. By using dual cross-linking by Ca²⁺ ions and chitosan, alginate particles were prepared by membrane emulsification to carry insulin for oral delivery [70 Zhang, 2011]. The alginate-chitosan microspheres were found to be promising carrier for oral administration of protein or peptide drugs by in vitro and in vivo tests demonstrating targeted drug delivery at intestinal level. BY using quaternized chitosan, the intestinal permeability of chitosan nanoparticles containing paclitaxel nanocrystals were improved [71 Lv, 2011]. Pickering emulsions with pH responsive properties have been produced by premix membrane emulsification using chitosan-coated alginate particles as emulsifiers [65 F. Nan et al., 2014]. The emulsions were pH dependent owing to the assembled pH-sensitive particles, and they can be stable at 4.6 < pH < 9. Uniform-sized pH-sensitive quaternized chitosan microspheres were prepared by combining SPG membrane emulsification technique and a thermal-gelation method. The obtained microsphere dissolved rapidly in acid solution (pH 5) and kept stable in neutral solution (pH 7.4) influencing the drug release behavior. Bovine serum albumin (BSA) used as a model drug was rapidly released in acid solution and slowly in neutral medium [52 Wu, 2008]. Ultrasound-assisted drug delivery is an emerging technique that has the advantage of being non-invasive, efficiently and specifically targeted and controllable [72 Sirsir SR, 2014]. Ultrasound contrast agents in the form of gas-filled microbubbles can be injected intravenously and can be applied to target drug delivery and enhancement of drug action. In a preliminary study, Pan et al., [73] (J. Pan, 2008) demonstrated the use of SPG membrane emulsification technique and ultrasound method to prepare ultrasound contrast agents based on a high molecular polymer-poly lactic acid (PLA) and loaded with Hydroxycamptothecin (HCPT) for cancer treatment.

The presence of biomolecules specific to disease state or an organ may be useful to regulate the release of drugs. A multiple emulsion containing a bio-receptor (Con A) that specifically recognizes and interacts with an artificial ligand (Glucose) was manufactured by the membrane process and used as a model system [64 Piacentini 2011]. Membrane emulsification has been used in the W/O and W/O/W emulsion preparation. Con A was adsorbed at emulsion droplet interface and the presence of additional molecules (such as other emulsifiers) contributed to emulsion stability. The progressive addition of glucose promoted the drug release, confirming the stimulus responsive property of the multiple emulsion. The system takes advantage from the mild operative conditions used for emulsion preparation preserving the biofunctional properties of Con A. The model system studied has a potential use as insulin controlled delivering systems for diabetes treatment.

Lipid nanoparticles for target organ delivery were designed by covalent conjugating, on the surface, a M-cell selective molecular signature, ulex europaeus agglutinin-1 (UEA-1), and a toll-like receptor (TLR)-agonist adjuvant monophosphoryl lipid (AMPL) to intimately interact with the mucosal mucosal dendritic cells [68 T. Ma, 2014]. The functionalization with UEA-1 allowed the almost exclusive adhesion to M-cells, leading to specific absorption and continuous retention in the target organ (gut) while the TLR-agonist MPL played a crucial role in up-regulating the phagocytosis of mucosal dendritic cells.

### Administration routes

Various routes of administration play a marked role in the bioavailability of the active drug for treatment of various diseases and disorders. An accurate control of particle size is especially required for parenteral administration (which includes intravenous, intramuscular, subcutaneous route as well as some specialized route i.e. intra-arterial). The size of particles must be significantly smaller than 5 µm in order to prevent embolism for intravenous applications. The preparation of micro and nano polycaprolactone particles in a size range between 2.35 µm and 210 nm was successfully achieved by using pulsed back-and-forward membrane emulsification [55 Imbrogno, 2014].Aqueous colloidal drug carrier dispersions based on nonpolar lipids for intravenous administration were produced by direct and premix SPG membrane emulsification method [74 S. Joseph, 2014]. Mean particle size below 500 nm and a particle size distribution completely in the nanometer range were only obtained using the membrane with the smallest pore size (0.1 µm) by the direct method. Instead, premix emulsification worked much better for the preparation of particles in the lower nanometer range with very short preparation time and reduced stress to the dispersion than the direct preparation method. An effective and safe formulation for the sustained-release of recombinant human growth hormone (rhGH) has been produced using poly(monomethoxypolyethylene glycol-co-d,l-lactide) (mPEG-PLA, PELA) microspheres [75 Y. Wei, 2012]. In vivo, subcutaneous administration test demonstrated that PELA microspheres have the potential to be clinically effective and safe when administered only once every two months, a dose regime for better patient acceptance and compliance. PELA microspheres produced by membrane emulsification have a potential to be used to reduce the frequency of medication as prolonged drug delivery device. Uniformly sized microparticles of poly(d,l-lactic-co-glycolic) (PLGA) acid, with controllable median diameters within the size range 40–140 micrometres, for subcutaneous controlled drug release were successfully prepared by membrane emulsification followed by solvent removal [76 G. Gasparini, 2008].
Subcapsular renal injection is a novel administration method for local delivery of therapeutics for the treatment of kidney related diseases. Poly[(D,L-lactide-co-hydroxymethyl glycolic acid) (PLHMGa) microspheres loaded with near-infrared dye-labeled bovine serum albumin (NIR-BSA) were prepared by premix membrane emulsification [77 F. Kazazi-Hyseni, 2015]. The produced microspheres provided a continuous release at the site of administration over a period of 3 weeks. Additionally, they demonstrated the potential to reduce side effects of therapeutic proteins by increasing the fluorescent signal at the site of injection and decreasing it elsewhere in the body.

The oral route remains the preferred route of administration to ensure patient satisfaction and compliance. However, the poor stability within the gastrointestinal tract or the poor solubility in gastrointestinal fluids, the low mucosal permeability, and/or the extensive first-pass metabolism can determine a low drug bioavailability after oral administration. Drug/carrier particulate systems are an attractive drug delivery strategy for highly potent drug substances normally unsuitable for oral use. By combining size control and size uniformity, achieved by membrane emulsification, with surface functionalization, by embedding the surface of nanoparticles (NPs) with one layer of phospholipids, T. Ma et al. reported the preparation of PLGA-lipid NPs as a promising oral vaccine delivery system [66 T. Ma, 2014]. A solid emulsion of itraconazole with increased solubility, release rate and oral bioavailability has been produced by combining SPG membrane emulsification with spray drying [78 Y-K Choi, 2012]. Drug topical administration is used to have a local target rather than systemic. However, many topically administered drugs have systemic effects, because they reach the circulation after being absorbed by the surrounding tissue. Topical medications are applied directly to the skin or mucous membranes (i.e. nasal, rectal, vaginal). Few examples are reported in literature on the use of membrane emulsification for the production of particles for inhalation therapy [79 Bao D.,]. For inhalation administration, required for both local and systemic drug delivery, aerosols with a size (aerodynamic diameter) ranging from 0.5 to 5 μm demonstrated efficient delivery to the lung whereas aerosols with a size of 2 μm around are capable of targeting the deep lung, i.e. alveolar region. Membrane emulsification has been successfully applied in the production of rifampicin-loaded PLGA microparticles for the inhalation therapy of tuberculosis [59, 80–82 Makino K, 2004; Ito, 2004, 2008, 2009]. Considering the strict restriction on the use of pharmaceutical excipients for inhalation therapy, engineered inhalable pure drug (i.e. carrier-free) particles in the form of nanoparticle agglomerates or relatively large porous drug particles (>5 μm) are currently under investigations. Membrane emulsification can support the research in this area to produce an efficient inhalation delivery system with superior aerosolisation and targeting capability.

As far as we are aware, no specific formulation for dermal application has been developed by membrane emulsification. However, the application of this technology offers new possibilities to produce finished dermal products with enhanced skin feel, creaminess, flow and other aspects of these products, which depend upon the droplet size and size distribution.

Improved Drug-loading efficiency / encapsulation efficiency
In the development of drug delivery systems, both drug-loading efficiency (DLE) and encapsulation efficiency (EE) have to be considered. The DLE is the ability of the matrix to entrap the drug and suitable particles for drug delivery should have high DLE in order to minimize administration and number of doses. On the other end, the EE describes the efficiency of the preparation method to incorporate the drug into the carrier system. For that reason, the DLE is an important parameter of the drug delivery systems influencing the rate and extent of drug release while the EE can be used to compare the efficiency of various processes used to incorporate the drug in a carrier.

Membrane emulsification provides highly efficient encapsulation because each droplet is formed individually, at low imposed shear and pressure. In a few papers, the EE obtained by using membrane emulsification and conventional mechanical stirring methods is compared [83-85 R. Liu, 2006; M. Matos, 2015; S. Ramakrishnan, 2013]. The EE was increased from 32.85% to 81.28% when membrane emulsification was used instead of the stirring method in the production of insulin-loaded PLA/PLGA microcapsules starting from W/O/W emulsions [83 R. Liu, 2006]. EE was considerably higher when membrane emulsification was applied in the second emulsification step, resulting in an increase of 24.7% and 8% for double emulsions containing resveratrol and vitamin B12, respectively [84 M. Matos, 2015]. When the rotor–stator was used, the encapsulation efficiency of fish oil was 17 or 22 % for whey protein isolate (WPI) and whey protein hydrolysate (WPH), respectively, while when ME was used the values increased to 29 % and 34–36 % for WPI and WPH, respectively [85 S. Ramakrishnan, 2013].

The effect of process parameters and chemical parameters during premix membrane emulsification on EE and DLE has been also investigated [86 Y. Yu, 2013]. After the preemulsion passed though the membrane more than three times, EE and DLE decreased from 81.8 ± 4.5 and 48.4% ± 3.3% for three cycles to 71.8 ± 7.7 and 20.7% ± 6.1%, for five cycles, respectively. EE and DLE decreased when high transmembrane pressure was used because preemulsion droplets break caused by the strong shear force generated. EE and DLE increased, with the increase of the stability of the molecular layer of surfactant in the oil–water interface (i.e. PVA) and as a function of amphipathic property of the polymer (PLA-TPGS respect to PLGA).

A.K. Pawlik and I.T. Norton [87 A.K. Pawlik, I.T. Norton, 2012] studied the effect on the encapsulation- efficiency of three different techniques: high-shear mixer, cross-flow membrane and rotating membrane for the secondary emulsification step in the production of duplex W1/O/W2 emulsions. It was shown that due to vigorous processing inside the cross-flow membrane module, emulsions prepared with this technique had similar encapsulation efficiency to emulsions prepared with a high-shear mixer while a rotating membrane demonstrated higher encapsulation efficiency.
Process and formulation parameters, which accelerate the solidification of the particles, will improve the EE of amphiphilic and hydrophilic drugs:

- **Polymer parameters:** polymer concentration, molecular weight, composition, polymer solubility in the solvent. Encapsulation efficiency increases with increasing polymer concentration and molecular weight as a result of the increased viscosity and faster solidification.

- **Drug parameters:** solubility of drug in the external phase, partition coefficient, drug-polymer interactions. The drug solubility into the external phase is important because it determines the maximum amount that can be dissolved in the external phase during the post-emulsification steps. Many drugs have some solubility in both water and oil phases, which may impact their physical and chemical stability. The partition of the drug between oil and water phases depends on solute type, solvent type, and environmental conditions, such as pH, ionic strength, dielectric constant, and temperature. In addition, the interaction between drug and polymer contributes to increasing encapsulation efficiency.

- **Solvent parameters:** solvent-non solvent relative solubility, ratio of solvent to non-solvent, the emulsifier. Selection of solvent system is based on solubility of polymer and type of solidification method of preparation used. The ‘high’ solubility of solvent into the non solvent allowed relatively fast mass-transfer between the dispersed and the continuous phases and led to fast precipitation of the polymer increasing the encapsulation efficiency. The volume of the non-solvent provides a high concentration gradient of the solvent across the phase boundary by diluting the solvent, leading to fast solidification of the particles. The emulsifier in the continuous phase or used during the post-emulsification treatment also can influence the encapsulation efficiency because it contributes to improve emulsion stability. However, the emulsifier can also increase the solubility of drugs in the continuous phase.

Figure 7 illustrates the important factors that contribute to the encapsulation efficiency.

The effect of several parameters that play a role in particle solidification, and consequently in drug encapsulation efficiency, has been studied in combination with the membrane emulsification process. In cases in which double emulsions have been used for the preparation of drug delivery systems such for vaccine delivery or protein delivery, the loss of proteins/peptides is mainly due to the water channels between the internal and external phase allowing the soluble biomolecules to diffuse through concentration gradient. The presence of a lipid layer structure has been demonstrated to make the Lipid NPs more efficient in protein loading [66 T. Ma, 2014] probably because the lipid molecules prevented protein diffusion during the formation of the pre-emulsion and during the evaporation of the solvent in the secondary step of solidification. R. Liu et al. demonstrated that the drug encapsulation efficiency was affected by the emulsion stability (correlated with PLA/PLGA ratio, NaCl concentration in outer water phase, inner water phase volume), pH-value in outer water phase (by modifying the solubility of the drug in the outer water phase) and the size of microcapsules (by modifying the specific surface between the emulsion droplets and the outer water phase became larger) [83 R. Liu, 2006]. Higher EE of PLGA colloidosomes was obtained in respect to the PLGA microcapsules (96.7% and 71.2%, respectively) [65 Nan, 2014]. This was a result of the high stability of the Pickering emulsion due to the irreversible adsorption of the particles (chitosan-coated alginate particles) at the interface, which offers an improved loading efficiency for insulin. Moreover, the particle-composed shell can act as a physical barrier preventing the leak of insulin from the internal water phase to the external water phase. Han et al. 2015 showed that the EE and the DLE of HCPT changed according to the weight ratio of chitosan and drug (when at 5:1 and 20:1, the entrapment efficiency were 75.2% and 90.4%, and the drug loading of drug were 12.4% and 4.2%), leading to either higher entrapment efficiency with lower drug loading or higher drug loading with lower entrapment efficiency and drug wasted [98 Han et al. 2015]. W. Wei et al found that the EE was reduced when a derivative N-[(2-hydroxy-3-trimethylammonium) propyl] chitosan chloride (HTCC) with a high degree of substitution was employed, because the presence of quaternized groups excludes the cross-linking reaction and thus leads to fewer cross-linked microspheres in the emulsion. However, steric hindrance by quaternized groups would also reduce leakage of
insulin from the microspheres during the cross-linking reaction and a higher DLE could be achieved [90 W. Wei, 2010].
Piacentini et al. showed that the EE is a function of the partition coefficient of the drug in the two phases that are used for emulsion preparation [35 Piacentini 2016]. The encapsulation efficiency for catechol and biophenols was 98% ± 1% and 92% ± 3%, that correspond to a partition coefficient between oil and water phase of 0.02 and 0.09, respectively.

APPLICATIONS
The most recent works on the use of membrane emulsification for the preparation of pharmaceutical particles are summarized in this section and they are described considering their final target application (Table 3).
<table>
<thead>
<tr>
<th>Type of particles</th>
<th>Membrane emulsification (ME) process</th>
<th>Therapeutic agent</th>
<th>Application</th>
<th>Particle size</th>
<th>Particle size distribution</th>
<th>Encapsulation efficiency</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>W/O/W emulsions</td>
<td>Direct ME</td>
<td>Doxorubicin</td>
<td>Cancer therapy</td>
<td>Dz = 0.440±0.007 µm</td>
<td>PDI = 0.220±0.087</td>
<td>EE % ~ 100%</td>
<td>93 R. Pradhan, 2014</td>
</tr>
<tr>
<td>W/O/W emulsions</td>
<td>Direct ME</td>
<td>Epirubicin hydrochloride</td>
<td>Cancer therapy</td>
<td>Dm = 30±0.71 µm</td>
<td>δ = 0.47±0.17</td>
<td>EE % = NA</td>
<td>94 S. Higashi, 1995</td>
</tr>
<tr>
<td>Chitosan nanospheres</td>
<td>Direct ME combined with cross-linking</td>
<td>Hydroxycamptothecin</td>
<td>Cancer therapy</td>
<td>Dm = 200-300 nm</td>
<td>PDI = 0.03</td>
<td>EE % = 90.4%</td>
<td>88 Han, 2015</td>
</tr>
<tr>
<td>Chitosan nanospheres</td>
<td>Direct ME combined with cross-linking</td>
<td>Paclitaxel</td>
<td>Cancer therapy</td>
<td>Dm = 130.27 ± 6.73</td>
<td>PDI = 0.034</td>
<td>EE% = 83.12 ± 4.89</td>
<td>71 Lv, 2011</td>
</tr>
<tr>
<td>PLA-TPGS nanoparticles</td>
<td>Pre-mix ME combined with solvent diffusion/evaporation</td>
<td>Docetaxel</td>
<td>Cancer therapy</td>
<td>Dm = 306.8 ± 5.5 nm</td>
<td>PDI = 0.098 ± 0.064</td>
<td>EE % = 81.8 ± 4.5%</td>
<td>86 Y. Yu, 2013</td>
</tr>
<tr>
<td>Lipid-PLGA nanoparticles</td>
<td>Direct ME combined with double emulsion–solvent evaporation method</td>
<td>Ovalbumin</td>
<td>-</td>
<td>Dm = 215.3 ± 3.5 nm</td>
<td>PDI = 0.048 ± 0.018</td>
<td>EE % = 95.3 ± 4.8%</td>
<td>66 T. Ma, 2014</td>
</tr>
<tr>
<td>PLA/PLGA microcapsules</td>
<td>Directed ME combined with double emulsion–solvent evaporation method</td>
<td>Insulin</td>
<td>Diabetes</td>
<td>Dm = 9 µm</td>
<td>PDI = NA</td>
<td>EE % = 81.28%</td>
<td>83 R. Liu, 2006</td>
</tr>
<tr>
<td>PELA microspheres</td>
<td>Premix ME combined with emulsion–solvent extraction</td>
<td>recombinant hepatitis B surface antigen</td>
<td>Vaccine</td>
<td>Dm = 1.13 ± 0.03 µm</td>
<td>CV = 18.9 %</td>
<td>EE % = 90.4 ± 4.3%</td>
<td>99 Q. Wei, 2008</td>
</tr>
<tr>
<td>PLA microparticles</td>
<td>Premix ME combined with emulsion–solvent extraction</td>
<td>H5N1 influenza split vaccine</td>
<td>Vaccine</td>
<td>Dm = 820 nm</td>
<td>-</td>
<td>-</td>
<td>60 Zhang, 2014</td>
</tr>
<tr>
<td>Chitosan microparticles</td>
<td>Premix ME and layer-by-layer (LbL) technology</td>
<td>anthrax protective antigen</td>
<td>Vaccine</td>
<td>Dm = 1002.1 ± 16.9 µm</td>
<td>-</td>
<td>-</td>
<td>103 Liu, 2013</td>
</tr>
<tr>
<td>PLA Microspheres</td>
<td>Premix ME combined with emulsion–solvent extraction</td>
<td>hepatitis B surface antigen</td>
<td>Vaccine</td>
<td>Dm = 800 nm</td>
<td>-</td>
<td>-</td>
<td>104 Chen, 2104</td>
</tr>
<tr>
<td>PLA Microspheres</td>
<td>Premix ME combined with emulsion–solvent extraction</td>
<td>hepatitis B surface antigen</td>
<td>Vaccine</td>
<td>Dm = 900 nm PDI = 0.0029</td>
<td>-</td>
<td>-</td>
<td>106 Liu, 2014</td>
</tr>
<tr>
<td>PELA microspheres</td>
<td>Premix ME combined with emulsion–solvent extraction</td>
<td>recombinant human growth hormone (rhGH)</td>
<td>Vaccine</td>
<td>Dm = 2.07 µm</td>
<td>PDI = 0.708</td>
<td>EE % = 89.3%</td>
<td>109 Y. Wei, 2011</td>
</tr>
<tr>
<td>Chitosan microspheres</td>
<td>Directed ME combined with</td>
<td>Insulin</td>
<td>Diabetes</td>
<td>Dm = 7.7 µm</td>
<td>CV = 10.9 %</td>
<td>-</td>
<td>100 W. Wei, 2010</td>
</tr>
<tr>
<td>Bioactives drug delivery systems: Lipophilic and Hydrophilic drugs encapsulation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Multiple S/O/W emulsion</strong></td>
<td>premix-SPG membrane emulsification</td>
<td>insulin</td>
<td>Diabetes</td>
<td>EE % = 63.5 %</td>
<td>101Tooritsaka, 2003</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nanoemulsions</strong></td>
<td>ME combined spray-drying technique</td>
<td>Flurbiprofen</td>
<td>Treatment of pain and inflammation caused by arthritis</td>
<td>Dm = 70nm</td>
<td>PDI = NA</td>
<td>EE % = NA</td>
<td>89 Oh, 2013</td>
</tr>
<tr>
<td><strong>O/W emulsion</strong></td>
<td>ME combined spray-drying technique</td>
<td>Silymarin</td>
<td>Antioxidant, and anti-cancer activity, liver protection</td>
<td>Dm = 214.3 ± 1.9 nm</td>
<td>PDI = 0.342 ± 0.001</td>
<td>EE % = NA</td>
<td>90 Yang KY, 2013</td>
</tr>
<tr>
<td><strong>PLGA microspheres containing</strong></td>
<td>ME combined with solvent evaporation method</td>
<td>rifampicin</td>
<td>Tuberculosis treatment</td>
<td>Dm = 4.31 μm</td>
<td>CV = 17.4%</td>
<td>LE % = 62.6%</td>
<td>59 F. Ito, 2008</td>
</tr>
<tr>
<td><strong>Chitosan nanoparticles</strong></td>
<td>ME combined with cross-linking method</td>
<td>Tacrine</td>
<td>Alzheimer</td>
<td>Dz = 90 nm</td>
<td>PDI = 0.22</td>
<td>EE % = 65%</td>
<td>91 S. Hassani, 2015</td>
</tr>
<tr>
<td><strong>Solid lipid microcapsules</strong></td>
<td>ME combined with cross-linking method</td>
<td>Vitamin B12</td>
<td>dietary supplement and to treat certain anemias</td>
<td>Dm = 17.50 μm</td>
<td>PDI = 0.4</td>
<td>EE % = 94.6%</td>
<td>53 M. Kukizaki, 2007</td>
</tr>
<tr>
<td><strong>Solid nanoemulsion</strong></td>
<td>ME with spray drying technique</td>
<td>Itraconazole</td>
<td>Mycosis</td>
<td>Dz =400-600 nm</td>
<td>PDI =0.15-0.4</td>
<td></td>
<td>78 Choi, 2012</td>
</tr>
<tr>
<td><strong>pNIPAM microcarriers</strong></td>
<td>ME combined with internal gelation</td>
<td>-</td>
<td>cell attachment</td>
<td>Dm = 98 μm</td>
<td>PDI = 0.19</td>
<td></td>
<td>39 M. P. Hanga, 2014</td>
</tr>
<tr>
<td><strong>bHb/BSA microspheres</strong></td>
<td>ME combined with cross-linking method</td>
<td>-</td>
<td>oxygen carriers</td>
<td>Dm = 3.9 μm</td>
<td>CV = 11%</td>
<td></td>
<td>46 Y. Lai, 2015</td>
</tr>
<tr>
<td><strong>PLLA microcapsules</strong></td>
<td>premix ME and double emulsion method</td>
<td>-</td>
<td>ultrasound imaging</td>
<td>Dm = 1-2 μm</td>
<td>CV = 11%</td>
<td></td>
<td>106 B. Liu, 2014</td>
</tr>
<tr>
<td><strong>PEG-PLGA microcapsules</strong></td>
<td>premix ME and double emulsion method</td>
<td>-</td>
<td>ultrasound/magnetic resonance bimodal imaging</td>
<td>Dm =3.7 μm</td>
<td>PDI = 0.03</td>
<td></td>
<td>107 S. Xu, 2015</td>
</tr>
</tbody>
</table>
with a narrow droplet diameter distribution and encapsulating vitamin B12 were prepared by a two-step membrane emulsification technique at a temperature higher than the melting point of the oil phase [53 M. Kukizaki, 2007]. A maximum EE of vitamin B12 of 97.7% was achieved and no leakage of vitamin B12 from the uniformly sized SLMCs was observed at body temperature. Monodisperse Ca-alginate microspheres were prepared using the membrane emulsification method to encapsulate three ionic types of drugs (Sodium salicylate (anionic), Lidocaine (cationic) and 4-acetamidophenol (non-ionic)) [40 You JO, 2001]. Lidocaine (cationic drug) release was more retarded than that of the anionic drug, because of the electrostatic attraction between the negative charge of the ionized carboxyl group in the alginate chain and the positive charge of the cationic drug. In an acidic release medium, a slow release was observed due to the low swelling characteristic and the increased viscosity of alginate, regardless of ionic type of drug.

**Anticancer drug delivery systems**

Anticancer drug delivery through smart, targeted micro and nanoparticles offers many attractive features, including: 1) improved delivery of lipophilic drugs; 2) targeted delivery of drugs in a cell- or tissue specific manner in order to improve treatment efficacy while minimize systemic side effects; 3) better protection of the drugs in the systemic circulation before they can reach the targets (e.g., the highly acidic environment in the stomach or the lysosomes of a cell, and the high levels of proteases or other enzymes in the blood stream); 4) controlled release as a function of target stimuli; and 5) co-delivery of multiple types of drugs and/or diagnostic agents (e.g., contrast agents) for combination therapy and real-time readout on the treatment efficacy [92 110 T. Sun, 2014]. The application of membrane emulsification technology is demonstrated to promote progress in the therapy of cancer by assessing some of the aforementioned goals.

Doxorubicin (DOX)-loaded W/O/W microemulsions were produced by Shirasu Porous Glass (SPG) membrane using W/O emulsions prepared by homogenization as feed emulsions [93 R. Pradhan, 2014]. The SPG membrane emulsification technique has been demonstrated as a promising technique for anticancer drug delivery. Indeed, the formulations showed a sustained release profile, prolonged the plasma drug concentration after intravenous administration to rats and gave about 17-fold higher area under the drug concentration–time curve (AUC) compared to free DOX solution.

Porous quaternized chitosan nanoparticles containing paclitaxel nanocrystals prepared by membrane emulsification demonstrated improved therapeutic efficacy in non-small-cell lung cancer after oral administration [71 Lv, 2011]. Chitosan nanoparticles prepared by premix SPG membrane emulsification technique demonstrated a potential use as a sustained release system for hydroxycamptothecin encapsulation in liver cancer treatment as well as for other anti-cancer drugs [88 J. Han, 2015].

Table 3. Particles produced by membrane emulsification explored as carriers for drug delivery (Dz: Z average; Dm: Median Particle Diameter; PDI: polydispersity index; δ: dispersion coefficient; NA: not available)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Type</th>
<th>Z average</th>
<th>M (nm)</th>
<th>PDI</th>
<th>δ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium salicylate</td>
<td>Sodium salicylate</td>
<td>200</td>
<td>200</td>
<td>0.5</td>
<td>0.3</td>
</tr>
<tr>
<td>Lidocaine</td>
<td>Lidocaine</td>
<td>500</td>
<td>500</td>
<td>0.4</td>
<td>0.2</td>
</tr>
<tr>
<td>4-acetamidophenol</td>
<td>4-acetamidophenol</td>
<td>1000</td>
<td>1000</td>
<td>0.6</td>
<td>0.4</td>
</tr>
</tbody>
</table>

The production at pilot scale of Docetaxel (DTX)-loaded poly(lactide)-d-α-tocopheryl polyethylene glycol 1000 succinate (PLA-TPGS) nanoparticles have been successfully achieved by using (SPG) premix membrane-emulsification technique [86 Y. Yu, 2013]. The tumor-inhibitory effect of the nanoparticles was studied in vivo in an H22 tumor-bearing mice model via intravenous administration. PLA-TPGS nanoparticles demonstrated superior pharmacokinetic and anticancer effects compared to the commercially available Taxotere.

W/o/w emulsions have been prepared to transport and deliver anticancer drugs for hepatocellular carcinoma [94, 95 Higashi, 1995, 2000]. The emulsion containing Iodinated Poppy-Seed Oil (IPSO) and Epirubicin hydrochloride was directly administered into the hepatic artery. Microdroplets accumulated only in hepatocellular carcinoma tissue and remained in the tissue for more than 3 weeks affecting tumour cells. The clinical tests showed a cancer volume decreased to a quarter of its initial size.

**Protein drug delivery systems**

Protein and peptide drugs have a number of potential applications as therapeutic agents instead of conventional chemical drugs such as low side effect, specific targeting site, low dosage, and so forth. However, protein and peptide drugs are generally characterized by a short biological half-life time, because they are easily hydrolysed or degraded by enzymes in vivo. Microencapsulation techniques have been developed to maintain serum drug concentration at a higher constant value for a prolonged time or to change injection formulation to orally or mucosally administered formulation.

A big challenge in protein drug delivery systems design is that the protein/peptide easily loses their bioactivity during preparation, storage, and release as a result of the shear force applied during emulsion preparation or protein unfolding /protein aggregation in the presence of an oil phase, oil/water interface, or hydrophobic surface [23 G. Ma, 2014]. The mild operative conditions of membrane emulsification technique can overcome the high shear force in conventional preparation method while opportune strategies have been developed for maintaining bioactivity of the encapsulated protein/peptide drugs. In particular, many strategies have been adopted to decrease the contact of protein molecules and hydrophobic interfaces: i) adding protection additives [96 F.T. Meng, 2004], ii) dispersing drug powder in oil phase [85 R. Liu, 2006], iii) designing amphiphilic block polymer PLA-PEG [96,75 F.T. Meng, 2004; Y. Wei, 2012], iv) optimizing
the solidification step [51, 96-98 F.T. Meng, 2004; J. Wu, 2006; L.Y. Wang, 2006; J. Wu, 2008], v) modifying the particle morphologies [99 W. Wei, 2008]. Uniform-sized biodegradable PLA/PLGA microcapsules loaded with recombinant human insulin (rHI) were successfully prepared by combining a Shirasu Porous Glass (SPG) membrane emulsification and a double emulsion-evaporation method [83 R. Liu, 2006]. Membrane emulsification provided tuning the size of microcapsules, adjusting the drug cumulative release profile by changing the size of microcapsules. Moreover, much higher encapsulation efficiency (91.82%) can be obtained when compared with the conventional mechanical stirring method. Colloidosomes have attracted significant attention as potential vehicles for the controlled delivery of active ingredients because their properties such permeability, mechanical strength, and environmental-sensitivity, can be easily tuned by selecting different particles as stabilizers. Uniform-sized Pickering emulsion stabilized with chitosan-coated alginate particles were prepared by premix membrane and used to produce colloidosomes as oral insulin delivery vehicles by the polymer deposition method [65 Nan, 2014]. The colloidosomes achieved a high EE of 97.6% and a pH sensitive drug release (slow in simulated gastric fluid and rapid in simulated intestinal fluid). Furthermore, animal testing confirmed the strong hypoglycemic effects of insulin-loaded colloidosomes even up to 6 h, suggesting colloidosomes as efficient oral insulin delivery vehicles.

The delivery of insulin by non-parenteral routes has gained significant attention over the last two decades. Hollow quaternized chitosan microspheres prepared by membrane emulsification and glutaraldehyde cross-linking have been developed as oral delivery of insulin [100 W. Wei, 2010]. Data demonstrated that microspheres were able to maintain the bioactivity of the encapsulated insulin, achieving bioadhesion of microspheres, increasing the loading ability and optimizing the release profile. In vivo tests demonstrated also an optimal reduction in blood glucose level and powerful therapeutic effects after oral administration of the designed microspheres. Multiple S/O/W emulsion for oral administration of insulin was produced by Toorisaka et al. [101 Toorisaka, 2003] with premix-SPG membrane emulsification. The monodisperse insulin multiple emulsions showed hypoglycemic activity for a long period after oral administration to rats. The authors indicated that the S/O/W emulsions with transforming insulin into a lipophilic complex and uniform droplets had good potential in the treatment of diabetes

Vaccine delivery
Application of particles prepared by membrane emulsification technique as the adjuvants of vaccine has attracted great attention in recent years, and has become an important new application field [21, 22Wang, 2015; Ma, G. (2014).]. Particles as vaccine adjuvants are used to protect the bioactivity of biomolecules, prolong their release profiles similar as the drug delivery system and to increase antigen uptake by antigen-presenting cells followed by facilitating the induction of potent immune responses. Membrane emulsification technology has been successfully applied in the design of particles as vaccine adjuvant. The size influence on immunity was eliminated due to uniform-sized microparticles with narrow size distributions obtained by membrane emulsifications. This helps in the understanding of the relevance of formulation parameters like materials, surface property of particle or the presence of surface active groups on the quantity and quality of immune response. Polymeric lipid NPs composed of a hydrophobic polymeric poly(D,L-lactide-co-glycolide) (PLGA) core and a surface coating of lipid monolayer as promising oral vaccine delivery system were produced by membrane emulsification and the double emulsion solvent evaporation method [67 T. Ma, 2014]. Compared with the pure PLGA NPs, the lipid NPs achieved higher DLE and EE for the encapsulated ovalbumin (OVA), used as a model vaccine. In vitro oral release studies showed the Lipid NPs were able to protect the loaded OVA from the harsh gastrointestinal environment for a long time. In addition, Lipid NPs showed higher affinity to the M-cells than PLGA NPs. Since the M-cells are crucial in particle translation as well as intimately associated with the underlying immune cells, the OVA-Lipid NPs effectively induced high level of IgG and IgA antibody responses. The ability of PLA-, PLGA-, and PELA based microparticles, produced by premix membrane emulsification, of inducing immune responses in vitro and in vivo has evaluated [102 Liu, 2013]. MP hydrophobicity has been demonstrated to be an important factor influencing the magnitude of immune responses induced by particulate used as vaccine adjuvants. Uniform-sized PLA microparticles were able to increase both humoral immune response and cell-mediated-immunity when used as adjuvants for H5N1 influenza split vaccine which might enhance crossprotection of influenza vaccine [61 Zhang, 2014]. Polycation surface modification also has been demonstrated to influence immune response. Higher surface charge of surface modified PLA microspheres produced by premix membrane emulsification led to increased antigen adsorption on MPs, promote antigen internalization into macrophages and activation, and facilitate phagocytic antigen localization independent of the lysosome, antibody and cytokine secretion [103, 104 Chen, 2014; Liu 2014]. Chitosan-based microparticles with abundant amino groups produced by premix-membrane emulsification contributed to complement activation and immune responses [105 Liu, 2013].

Tissue engineering
Membrane emulsification technology has many potential advantages for the manufacturing of cell delivery systems in non-denaturating conditions and highly controlled production. Membrane emulsification is emerging as an effective technique for the production of particles in a size range of interest as scaffolds for various biopharmaceutical applications,
including, microcarriers for cell culture by particle surface functionalization or by encapsulation. Membrane emulsification and internal gelation have been used at batch scale to produce uniform calcium alginate particles with controllable median diameters as microcarriers for cell attachment [39 M. P. Hanga, 2014]. The thermoresponsive properties of beads by amine terminated poly N-isopropylacrylamide (pNIPAM) functionalization promoted cells detachment from the bead surface by simply lowering the temperature within the system to below the phase transition temperature. This study demonstrated the potential use of this technique for stem cell growth and recovery without the need for enzymatic based cell release.

An artificial oxygen carrier composed of bovine hemoglobin (bHb) and bovine serum albumin (BSA) were prepared by SPG membrane emulsification and their subsequent cross-linking by glutaraldehyde [46 Y. Lai, 2015]. The microspheres showed a narrow size distribution (the CV of the microsphere size was around 10%) and good biocompatibility. The biomolecules maintained their ability to bind and release oxygen. Because particle size ranged from 3.9 to 4.9 µm, bHb-BSA microspheres are expected not to be uptaken by cells, they can be applied as oxygen carriers in cell culture in the future. Cytotoxicity tests in vitro demonstrated a relationship between the microsphere size and the cytotoxic effect [46 Y. Lai, 2015]. Microsphere diameter of 18.3 µm showed good cellular compatibility regardless of the oxyhemoglobin percentage. Since cytotoxicity is a crucial factor in their applications, a systemic investigation would provide a new insight into the design of HBOCs.

Biomedical imaging
Gas-filled microcapsules have superior scattering properties compared with blood cells and the differences of compressibility and density between the microcapsules and the surrounding fluid make the microcapsules highly echogenic. The ultrasonic properties of the microcapsules are significantly dependent on their size and size distribution. B. Liu et al [106 B. Liu, 2014] adopted a premix membrane emulsification technique and double emulsion method to prepare uniform biodegradable polylactone microcapsules for enhancement of ultrasound intensity and duration. The effects of various process parameters on the size and size distribution for optimizing and scaling up the preparation of diverse uniform sized polylactone microcapsules. 4 µm PLLA (poly(L-lactide)) microparticles prepared by using the optimized conditions were considerably stronger and longer than those of commercially available ultrasound contrast agents. Enhanced multimodal imaging such as ultrasound imaging and magnetic resonance imaging have attracted great interests in recent years to achieve more abundant pathological information for accurately diagnosing complicated diseases. Premix membrane emulsification method was used to prepare uniform PEG-PLGA microcapsules with superparamagnetic Fe3O4 NPs embedded in the shell for ultrasound/magnetic resonance bimodal imaging [107 S. Xu, 2015]. The produced particles demonstrated improved stability in physiological solutions, simultaneously performance enhancement of ultrasound imaging and magnetic resonance imaging, no appreciable cytotoxicity and embolism to mice even at high dose. NIR emitting CdSeTe/CdS/ZnS core/shell/shell quantum dot-encoded microbeads combined with common flow cytometry with one laser for multiplexed detection of HBV (hepatitis B virus) have been produced by membrane emulsification [108 Wang, X, 2013]. The particles have the potential to replace current multiple lasers based detection system.

Conclusions
Membrane emulsification is increasingly used for the production of single and multiple emulsions and solidified particles as carriers for drug delivery. The advantages of membrane emulsification in pharmaceutical particles production are in uniform and controlled particle size, mild operative conditions during droplet generation, increased encapsulation efficiency.

The wide range of strategies employed to control the shear at the membrane surface and to obtain high production rates with droplet size uniformities and target droplet to pore size ratio are a powerful tool for pharmaceutical industry to design particles with tuned properties.

The recent technical advancements in membrane emulsification technology, with particular reference to reliability and ability to scale production, are expected to promote the development of smart, targeted micro/nanoparticles as drug carriers significantly improving particles using sophisticated particle and process design in the pharmaceutical field.
References

1 Piacentini E, Drioli E, Giorno L. Membrane emulsification technology: Twenty-five years of inventions and research through patent survey, J Membr Sci 2014; 468: 410-422.


4 Dragosavac MM. Membrane emulsification and filtration for engineered particles. Doctoral dissertation, © Marijana Dragosavac. 2011, Loughborough University


79 Bao D., Zhao, Y. Building Membrane Emulsification into Pulmonary Drug Delivery and Targeting, Pharmaceutical Research 2010, 27:2505–2508


85 S. Ramakrishnan M.F., Aceña-Muñoz L., De Lamo-Castellví S., Güell C., Fish Oil Microcapsules from O/W Emulsions Produced by Premix Membrane Emulsification, Food Bioprocess Technol 6 (2013) 3088–3101


26


